Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 2500 Index

Published on 06/29/2025 at 22:03 

Share 

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 2500 Index

Share © S&P Capital IQ - 2025 


<h3><a> Latest news about Eledon Pharmaceuticals, Inc. </a></h3>

<table>
<tbody>
<tr>
<td><a> Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 2000 Growth Index </a></td>
<td>1h ago</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 2500 Index </a></td>
<td>2h ago</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 </a></td>
<td> May. 14</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 </a></td>
<td> Mar. 20</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals FY Operating Expenses USD 70.577 Million </a></td>
<td> Mar. 20</td>
<td> RE </td>
</tr>
<tr>
<td><a> Guggenheim Initiates Eledon Pharmaceuticals at Buy With $9 Price Target </a></td>
<td> Jan. 28</td>
<td> MT </td>
</tr>
<tr>
<td><a> Certain Preferred Stock of Eledon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2025. </a></td>
<td> Jan. 27</td>
<td> CI </td>
</tr>
<tr>
<td><a> Certain Common Warrants of Eledon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2025. </a></td>
<td> Jan. 27</td>
<td> CI </td>
</tr>
<tr>
<td><a> Certain Pre-Funded Warrants of Eledon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2025. </a></td>
<td> Jan. 27</td>
<td> CI </td>
</tr>
<tr>
<td><a> Certain Common Stock of Eledon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2025. </a></td>
<td> Jan. 27</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 </a></td>
<td> Nov. 12</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals Reports Positive Data in Type 1 Diabetes Study; Shares Rise </a></td>
<td> 24-10-29</td>
<td> MT </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial At UChicago Medicine </a></td>
<td> 24-10-29</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients </a></td>
<td> 24-09-04</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 </a></td>
<td> 24-08-19</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt </a></td>
<td> 24-08-18</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection </a></td>
<td> 24-07-29</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. announced that it has received $2.099993 million in funding </a></td>
<td> 24-07-07</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 3000E Index </a></td>
<td> 24-06-30</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell Microcap Index </a></td>
<td> 24-06-30</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell Microcap Value Index </a></td>
<td> 24-06-30</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 3000E Value Index </a></td>
<td> 24-06-30</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation </a></td>
<td> 24-06-03</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 </a></td>
<td> 24-05-13</td>
<td> CI </td>
</tr>
<tr>
<td><a> Eledon Pharmaceuticals, Inc. announced that it has received $49.99901 million in funding </a></td>
<td> 24-05-08</td>
<td> CI </td>
</tr>
</tbody>
</table>

<h3><a> Chart Eledon Pharmaceuticals, Inc. </a></h3>

<label>Duration</label>
<select>
<option>Auto.</option>
<option>2 months</option>
<option>3 months</option>
<option>6 months</option>
<option>9 months</option>
<option>1 year</option>
<option>2 years</option>
<option>5 years</option>
<option>10 years</option>
<option>Max.</option>
</select>

<label>Period</label>
<select>
<option>Day</option>
<option>Week</option>
</select>

<a> ELDN: Dynamic Chart </a>

<h2><a> Company Profile </a></h2> Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Companyâs lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Eledon Pharmaceuticals, Inc.(NasdaqCM: ELDN) added to Russell 2500 Index

Eledon Pharmaceuticals, Inc. (NasdaqCM: ELDN) was added to the Russell 2500 Index, reflecting its growth and market recognition. The company reported earnings results for multiple quarters in 2024 and 2025, highlighted clinical trials for its lead drug tegoprubart, and secured $49.999 million in funding in 2024 and $2.099993 million in 2025.